< Back to previous page

Publication

The effect of Anakinra on Quality-of-Life in a family with colchicine-resistant FMF

Journal Contribution - Journal Abstract Conference Contribution

About 5-10% of patients with FMF do not to colchicine treatment to control inflammation. In these patients anti-IL1 therapy seems to be effective in controlling inflammation, although clinical trials are lacking. However, many patients on Anakinra experience side effects including headache and injection-site reactions. How Anakinra treatment influences quality-of-life (QoL) in these patients is unknown.
Journal: Pediatric Rheumatology
Issue: 1
Volume: 13
Pages: 108 - 108
Publication year:2015
Accessibility:Open